Sponsor Responsibility I - Good Clinical Practice (GCP)

Comprehensive practice flashcards covering Sponsor Responsibilities under Good Clinical Practice (GCP), including trial design planning, agreements, investigator selection, regulatory and IRB communications, sponsor oversight, quality management systems, QA audits, and trial financing.

According to GCP, what entities can be defined as a sponsor of a clinical trial?

An individual, company, institution, or organisation which takes responsibility for the initiation, management, and/or financing of a clinical trial.

Under regulatory requirements, how many sponsors is a clinical trial permitted to have?

A clinical trial may have one or several sponsors where permitted under regulatory requirements.

What does the abbreviation "IIT" stand for in the context of a Sponsor-Investigator?

Investigator-Initiated Trial.

How is a "Sponsor-Investigator" defined in clinical trials?

An individual who both initiates and conducts, alone or with others, a clinical trial, and under whose immediate direction the investigational product is administered to, dispensed to, or used by a trial participant.

Can a corporation or agency be considered a "Sponsor-Investigator"?

No. The term does not include any person other than an individual (e.g., it does not include a corporation or an agency).

What dual obligations must a Sponsor-Investigator fulfill?

The obligations of a sponsor-investigator include both those of a sponsor and those of an investigator.

To gain a basic understanding of the sponsor's responsibilities in various aspects of the conduct of a clinical trial.

In Relationship Model 1 (without a CRO), what is the direct operational relationship between the Sponsor and the Investigator?

Engage (the Sponsor engages the Investigator).

In Relationship Model 1, what action does the Sponsor carry out toward the Clinical Trials?

Monitor.

In Relationship Model 1, what action does the Investigator carry out toward the Clinical Trials?

Conduct.

In the clinical trial relationship diagram shown, what are the primary actions linking Sponsor, Investigator, and Clinical Trials?

The Sponsor engages the Investigator and monitors the Clinical Trials, while the Investigator conducts the Clinical Trials.

What does the abbreviation "CRO" stand for?

Contract Research Organisation.

In Relationship Model 2 (involving a CRO), what interaction occurs from the Sponsor to the CRO?

Engage (the Sponsor engages the CRO).

In Relationship Model 2, what action does the CRO perform regarding the Investigator?

Select (the CRO selects the Investigator).

In Relationship Model 2, which entity monitors the Clinical Trials?

The CRO monitors the Clinical Trials.

In the governance structure shown in this diagram, what are the two roles assigned to the CRO?

The CRO selects the Investigator and monitors the Clinical Trials.

In Relationship Model 3 between Sponsor, CRO, and Investigator, which parties monitor the Clinical Trials?

Both the Sponsor and the CRO monitor the Clinical Trials.

How does the monitoring pathway in this diagram (Relationship Model 3) differ from Relationship Model 2?

In this model, both the Sponsor and the CRO monitor the Clinical Trials directly, whereas in Model 2 only the CRO monitors the Clinical Trials.

What data must the sponsor ensure is available during trial design planning to support human exposure?

Sufficient safety and efficacy data (e.g., from nonclinical studies and/or clinical trials and/or real-world sources).

What three specific parameters of human exposure must available safety and efficacy data support during trial design planning?

Route, dosages, and treatment duration.

Whose inputs should the sponsor consider during trial design planning?

Inputs from a wide variety of interested parties such as healthcare professionals.

How should a sponsor incorporate quality into the design of a clinical trial?

By identifying factors that are critical to the quality of the trial and by managing risks to those factors.

What practical feasibility standard must trial design satisfy?

It must be operationally feasible.

What should trial design planning actively avoid to remain efficient?

Avoid unnecessary complexity, procedures, and data collection.

What three qualities should protocols, data acquisition tools, and other operational documents exhibit?

They should be clear, concise, and consistent.

When should the sponsor define, establish, and allocate all trial-related activities?

Prior to initiating a trial.

What is the sponsor's responsibility regarding trial resources?

Ensure that sufficient resources are available to appropriately conduct the trial.

What examples of qualified individuals should the sponsor utilise throughout all stages of the trial process?

Biostatisticians, clinical pharmacologists, and physicians.

Across which specific trial stages must qualified individuals be utilised by the sponsor?

Designing the protocol, Case Report Forms (CRFs), and analysing and preparing interim & final clinical trial reports, etc.

What is the sponsor's responsibility regarding trial-related medical questions or problems?

Designate appropriately qualified medical personnel who will be readily available to advise on specific trial-related medical questions or problems.

If necessary, who may the sponsor appoint to advise on trial-related medical questions or problems?

Outside consultant(s) may be appointed for this purpose.

How must the financial aspects of a clinical trial be formalized?

The financial aspects of the trial should be documented in an agreement between the sponsor and the investigator / institution.

What compliance obligation must be stated in the agreement between the sponsor and the investigator/institution/service provider?

To conduct the trial in compliance with the approved protocol and in compliance with GCP and applicable regulatory requirement(s).

What procedure compliance obligation regarding data must be included in the trial agreement?

To comply with procedures for data recording / reporting.

How long must the investigator, institution, or service provider retain trial-related essential documents?

Until the sponsor informs the investigator / institution / service provider that these documents are no longer needed.

What auditing and review permissions must the agreement between sponsor and investigator/institution grant?

To permit monitoring and auditing by sponsors, inspections by regulatory authorities (domestic and foreign), and review by IRBs/IECs.

What access rights must be provided by investigators and service providers under the sponsor agreement?

Providing direct access to source records and facilities, including to those of service providers.

What trial-related duties and functions may a sponsor transfer to a service provider (e.g., CRO)?

A sponsor may transfer any or all of the sponsor's trial-related duties and functions to a service provider.

What happens to trial-related activities that are not specifically transferred to a service provider?

Trial-related activities that are not specifically transferred are retained by the sponsor.

Where does the ultimate responsibility for the sponsor's trial-related activities reside when duties are transferred to a service provider?

Ultimate responsibility for the sponsor's trial-related activities resides with the sponsor.

In what form must any duty and function transferred to a service provider be specified?

Any duty and function that is transferred should be specified in writing.

What must a service provider implement according to the agreement with the sponsor?

The service provider should implement appropriate quality management.

What must a service provider report to the sponsor regarding trial incidents?

Report to the sponsor incidents that might have an impact on the safety of trial participants or/and trial results.

Who is responsible for assessing the suitability of and selecting the service provider?

The sponsor.

What documentation must the sponsor provide to service providers?

Provide the service providers with the protocol and any other documents required for them to perform their activities.

What is the sponsor's oversight obligation concerning transferred activities?

The sponsor must ensure oversight of important trial-related activities that are transferred to service providers.

In accordance with what standards must trial-related activities performed by service providers be conducted?

In accordance with relevant GCP requirements.

What is required in clinical trials that have more than one sponsor?

They should have a documented agreement that sets out their respective responsibilities.

Who is responsible for selecting the investigator(s) and institution(s)?

The sponsor.

By what qualifications must a selected investigator be assessed?

Qualified by training and experience.

What resource requirement must an investigator/institution meet to properly conduct a trial?

Adequate resources to properly conduct the trial.

What must be selected and documented for multicentre trials regarding investigators?

Selection of co-ordinating investigator(s), whose roles and responsibilities should be documented.

What documents must the sponsor provide to the selected investigator(s)/institution(s)?

The protocol and an up-to-date Investigator's Brochure.

What must the sponsor grant investigators regarding the protocol and supplied information prior to trial conduct?

Sufficient time to review the protocol and the information provided.

What investigator-specific attribute is considered as a factor in investigator selection?

Reputation of the investigator in his/her field of expertise.

What site infrastructure elements are evaluated during investigator selection?

Availability of infrastructure at the clinical trial site for conduct of the study, including equipment and trained staff.

Why is the availability of the trial participant population an important selection factor?

For timely enrollment of the trial participants in the trial.

How does site accessibility affect investigator selection?

Through the ease of accessibility of the trial site to the sponsor.

What institutional ethics factor is evaluated during investigator selection?

The ability of the EC/IRB to execute all its responsibilities.

What timeline factor is considered when selecting an investigator?

Anticipated time required to start and complete the trial.

What three cost components are considered under the budget factor during investigator selection?

Investigator fees, coordinator fees, and specific procedure charges.

When there is a change of Principal Investigator (PI), who must the current PI inform?

The current PI must inform the sponsor, EC, and RA.

What information must the current PI furnish to the sponsor, EC, and RA during a PI change?

Furnish them with particulars of the new PI.

What must the new Principal Investigator obtain before conducting any trials?

The new principal investigator must be issued with a new CTA/CTN/CTC before conducting any trials.

Which regulatory body issues the new CTA/CTN/CTC for a new Principal Investigator?

HSA (Health Sciences Authority).

What must the sponsor do prior to initiating clinical trial(s) regarding Regulatory Authorities?

Submit application(s) to the RA for review acceptance and/or permission to begin the trial(s).

What two elements must be included on any notification or submission to Regulatory Authorities?

Any notification/submission should be dated and contain information to identify the protocol.

What confirmation must the sponsor obtain regarding the IRB before initiating a trial?

Need to confirm that approval was issued from the IRB.

From whom does the sponsor obtain the IRB approval letter?

To obtain the IRB approval letter from the investigator.

In whose name is the IRB approval letter issued?

The IRB approval letter is issued in the name of the investigator.

What identity details of the relevant IRB/IEC must the sponsor record?

The name and address of the relevant IRB/IEC.

What formal statement regarding the IRB/IEC must the sponsor maintain in its records?

A statement that it is organised and operates according to GCP and applicable regulatory requirements.

What trial status documentation regarding the IRB/IEC must be maintained by the sponsor?

Documented initial and subsequent IRB/IEC approval/favourable opinion, as well as any termination of the trial or suspension of approval/favourable opinion.

If the EC conditions its recommendation upon changes to the trial, what must the sponsor obtain from the investigator?

A copy of the modification(s) made and the date the recommendation was given by the EC.

What specific trial materials may require modification based on EC recommendations?

Modification(s) of the protocol, written informed consent form, and any other written information to be provided to trial participants, and/or other procedures.

What are the three core objectives of sponsor oversight regarding trial conduct and generated data?

To ensure reliable trial results, trial participants' safety, and appropriate decision making.

Under sponsor oversight, what three standards must trial processes comply with?

The trial protocol, regulatory requirements, and ethical standards.

What must the sponsor establish regarding protocol deviations (PD)?

Determine trial-specific criteria for classifying protocol deviations (PD) as important.

What defines an "important" protocol deviation with respect to trial data?

Deviations that may significantly impact the completeness, accuracy, and/or reliability of the trial data.

What defines an "important" protocol deviation with respect to participants?

Deviations that significantly affect a participant's rights, safety, or well-being.

How should the range and extent of sponsor oversight measures be designed?

Fit for purpose and tailored to the complexity of and risks.

Whose trial-related activities are subject to quality assurance and quality control under sponsor oversight?

Trial-related activities of investigators and service providers.

Why is timely escalation and follow-up of issues necessary under sponsor oversight?

To allow the implementation of corrective actions in a timely manner.

What committee may a sponsor establish to assess trial progress and safety at intervals?

Independent Data Monitoring Committee (IDMC).

What two categories of data does an IDMC assess at intervals during a trial?

Safety data and efficacy endpoints.

What recommendations does an IDMC provide to the sponsor after evaluating trial progress?

To recommend whether to continue, modify, or stop a trial.

Across which stages of the trial process must a sponsor implement a Quality Management system?

Throughout all stages of the trial process.

What two key areas must Quality Management focus on during trial activities?

Trial participant protection and reliability of trial results.

Where should the sponsor describe the quality management approach implemented for the clinical trial?

In the clinical trial report.

What three areas are included within Quality Management (QM)?

The design of trial protocols; tools and procedures for data collection and processing; and collection of information essential to decision making.

What type of approach should the Quality Management system employ?

A risk-based approach.

What are the six components of the risk-based approach in Quality Management?

Risk Identification, Risk Evaluation, Risk control, Risk communication, Risk review, and Risk reporting.

What is the sponsor responsible for establishing, implementing, and maintaining to ensure trial compliance?

QA and QC systems with written SOPs.

What three aspects of trial execution must QA & QC systems with written SOPs safeguard?

To ensure that trials are conducted, and that data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and applicable regulatory requirement(s).

How should a sponsor's audit be positioned relative to routine monitoring?

The sponsor's audit should be independent of and separate from routine monitoring.

What is the purpose of conducting a sponsor's audit?

To evaluate whether the processes put in place to manage and conduct the trial are appropriate and to ensure compliance with the protocol, GCP, and applicable regulatory requirements.

What are the qualification and independence criteria for selecting auditors?

Auditors must be independent of the clinical trial/processes being audited and qualified by training and experience to conduct audits properly.

In accordance with what must audits be conducted, and what document should be provided following an audit?

Audits must be conducted in accordance with sponsor SOPs, and the auditor should provide an audit certificate.

What access agreement is the sponsor responsible for securing from all involved parties?

Direct access to all trial-related sites, source data / documents, and reports for monitoring and auditing by the sponsor, and inspection by domestic and foreign regulatory authorities.

What legal and financial protections must the sponsor provide to the investigator/institution, and what are the exclusions?

Provide insurance or indemnify (legal and financial coverage) the investigator / institution against claims arising from the trial, except for claims that arise from malpractice and/or negligence.